ADVERTISEMENT
Get Started
  • About Homebase Tv | Hbtvghana.com
  • Advertise
  • Broadcast Live
  • Disclaimer
  • Privacy & Policy
  • Terms and Conditions
  • Vacancies
  • Contact Us – Connect With Us
Homebase Tv - Hbtvghana.com
  • Home
  • General News
  • Business News
  • Health
  • Life & Style
  • Politics
    • Press Release
    • Parliament
  • Sports
No Result
View All Result
  • Home
  • General News
  • Business News
  • Health
  • Life & Style
  • Politics
    • Press Release
    • Parliament
  • Sports
No Result
View All Result
Homebase Tv - Hbtvghana.com
No Result
View All Result
ADVERTISEMENT
ADVERTISEMENT

Landmark deal paves way for cheaper HIV protection jab

Wed, Sep 24 2025 2:33 PM
in Ghana General News, International, News
landmark deal paves way for cheaper hiv protection jab
0
SHARES
0
VIEWS
Share on FacebookShare on TwitterShare on TelegramShare on Whatsapp
ADVERTISEMENT

Landmark deal paves way for cheaper HIV protection jab

A new HIV prevention drug will be made available at a lower cost in over 100 low-income countries within two years — a move expected to give millions access to the breakthrough treatment and potentially bring the world closer to ending the HIV/Aids epidemic.

The drug, called Lenacapavir and administered by injection, is due to be rolled out as early as the end of this year, at a cost of $28,000 (£20,000) per person annually.

But Wednesday’s announcement promises to slash that price to just $40 — around 0.1% of the original cost. The lower-cost version will be rolled out in 2027 across 120 low- and middle-income countries.

Scientists say the drug stops the virus from replicating inside cells.

The landmark deal to provide cheaper antiretroviral drugs for people with HIV in developing countries was brokered by former US President Bill Clinton after negotiations with pharmaceutical companies.

ReadAbout

NCPTA warns against “religious bias” in schools, calls for urgent policy reform

American climber among two dead after fall from New Zealand’s highest mountain

Kumasi High court told Daddy Lumba died a German national, not Ghanaian

The agreement announced on Wednesday was reached between the Clinton Health Access Initiative in partnership with the Gates Foundation and other groups, including South African research institute, Wits RHI.

“For many low- and middle-income countries, affordable access to HIV prevention is not a luxury, it is a necessity,” Professor Saiqa Mullick from Wits RHI told the BBC.

She added that Lenacapavir had “the potential to transform prevention, especially for young people and underserved communities who struggle with frequent clinic visits.

“The real work begins now, partnering with communities and governments to build demand, secure commitments, and prepare systems so countries are ready for rapid introduction and scale.”

Lenacapavir has delivered impressive trial results and, in July, it received official backing from the World Health Organization for HIV prevention.

The injection is taken twice a year and provides six months of protection against HIV infection at a time.

Experts say long-acting injectables like Lenacapavir could help reduce new infections in populations that are most vulnerable, including adolescent girls and young women, LGBT people, sex workers, and those who use drugs.

It is hoped it will replace the current form of HIV preventative drug, know as PrEP, or pre-exposure prophylaxis, which is taken orally and also costs $40 per person each year.

The pills are taken daily, which can be difficult for patients to consume, and can carry stigma in certain societies. The daily dose also makes it harder to access consistently. According to the Gates Foundation, only 18% of those who could benefit from PrEP currently have access.

Lenacapavir has already been approved by the US Food and Drug Administration and the European Commission this year.

Last year June, the US drug company Gilead announced that a trial of its HIV drug Lenacapavir had a 100% success rate.

The new, generic version is still pending regulatory approval but it is hoped it will be available within 18 months.

One study says that increasing access to the injection to just 4% of the population could prevent up to 20% of new HIV infections.

The drug can be used to protect people from catching the virus, but also to treat those who have it, according to scientists.

The announcement comes amid a turbulent year for global health, particularly the fight against HIV and Aids, following swingeing cuts by the US government’s foreign aid programme, USAID, under the Trump administration.

According to UNAIDS, more than 40 million people are currently living with HIV.

Despite huge strides made to reduce global HIV rates and AIDS-related deaths since 2000, about 1.3 million people still contracted HIV last year, and more than 600,000 people died from AIDS-related illnesses.

South Africa remains the country with the highest number of HIV cases, with almost eight million people living with the virus. It will be one of the countries to access the new, cheaper drug.

South Africa’s department of health told the BBC that it “supports any efforts to make life saving treatment like Lenacapavir available and accessible at affordable rate to all countries, including low and middle income countries, as and when they need it”.

  • President Commissions 36.5 Million Dollars Hospital In The Tain District
  • You Will Not Go Free For Killing An Hard Working MP – Akufo-Addo To MP’s Killer
  • I Will Lead You To Victory – Ato Forson Assures NDC Supporters

Visit Our Social Media for More

About Author

c16271dd987343c7ec4ccd40968758b74d64e6d6c084807e9eb8de11a77c1a1d?s=150&d=mm&r=g

hbtvghana

See author's posts

Discover interesting ones too

Average lending rates fall sharply to 22.22% in October 2025

Average lending rates fall sharply to 22.22% in October 2025

0
NCPTA warns against “religious bias” in schools, calls for urgent policy reform

NCPTA warns against “religious bias” in schools, calls for urgent policy reform

0

American climber among two dead after fall from New Zealand’s highest mountain

Ghana’s insurance industry remains underdeveloped despite potential – Deloitte Insurance Outlook

Kumasi High court told Daddy Lumba died a German national, not Ghanaian

Warner settles lawsuit with AI music firm and launches joint venture

Warner settles lawsuit with AI music firm and launches joint venture

Dr Kingsley Agyemang pays medical bills for patients at Kyebi Gov’t Hospital to mark his birthday

Burned at age 10, stigmatised but unafraid of never getting a husband – A burn survivor’s story

UK bans 1,632 Ghanaians for visa fraud

  • Dr. Musah Abdulai: If the Chief Justice returns: Will it lead to reset, redemption, or rupture?

    Dr. Musah Abdulai: If the Chief Justice returns: Will it lead to reset, redemption, or rupture?

    0 shares
    Share 0 Tweet 0
  • Haruna Iddrisu urges review of salary disparities between doctors in academia and health service

    0 shares
    Share 0 Tweet 0
  • No justification for higher GAF entry age – Col. Festus Aboagye (Rtd.)

    0 shares
    Share 0 Tweet 0
  • Farewell, River Ayensu

    0 shares
    Share 0 Tweet 0
  • We are coming for you – CID boss tells criminals

    0 shares
    Share 0 Tweet 0
ADVERTISEMENT
ADVERTISEMENT

Follow Homebase Tv

  • About Homebase Tv | Hbtvghana.com
  • Advertise
  • Broadcast Live
  • Disclaimer
  • Privacy & Policy
  • Terms and Conditions
  • Vacancies
  • Contact Us – Connect With Us

© 2014 Total Enjoyment & Proper News

No Result
View All Result

© 2014 Total Enjoyment & Proper News

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.